Peter S. Goldfarb

3.4k citations

90 papers · 2.8k indexed · 1 hit paper · h-index 31

Molecular Biology top 10%
Pharmacology top 0.2%
Health, Toxicology and Mutagenesis top 2%
Nutrition and Dietetics top 2%
Oncology top 10%

Co-authors: Peter Eddershaw Michael H. Tarbit David F. Lewis Nabeel A. Affara Paul R. Harrison Ian Chambers Jon Frampton David R. Livingstone
Topics: Pharmacogenetics and Drug Metabolism (33 papers)Drug Transport and Resistance Mechanisms (18 papers)Computational Drug Discovery Methods (12 papers)
Cited by: Pharmacology Health, Toxicology and Mutagenesis Biochemistry
Journals: Nature Proceedings of the National Academy of Sciences Nucleic Acids Research
Partner nations: United Kingdom United States Sweden

In The Last Decade

Peter S. Goldfarb

89 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The structure of the mouse glutathione peroxidase gene: the selenocysteine in the active site is encoded by the ‘termination’ codon, TGA.

1986 512 citations Peter S. Goldfarb et al. profile →

Peers

Countries citing papers authored by Peter S. Goldfarb

Since Specialization

Citations

This map shows the geographic impact of Peter S. Goldfarb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter S. Goldfarb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter S. Goldfarb more than expected).

Fields of papers citing papers by Peter S. Goldfarb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter S. Goldfarb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter S. Goldfarb. The network helps show where Peter S. Goldfarb may publish in the future.

Co-authorship network of co-authors of Peter S. Goldfarb

This figure shows the co-authorship network connecting the top 25 collaborators of Peter S. Goldfarb. A scholar is included among the top collaborators of Peter S. Goldfarb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter S. Goldfarb. Peter S. Goldfarb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigating Human P450s Involved in Drug Metabolism via Homology with High-Resolution P450 Crystal Structures of the CYP2C Subfamily 2006 ·Current Drug Metabolism ·D. F. V. Lewis,Yuko Ito,Peter S. Goldfarb	9
2	Structural Modelling of the Human Drug-Metabolizing Cytochromes P450 2006 ·Current Medicinal Chemistry ·D. F. V. Lewis,Yuko Ito,Peter S. Goldfarb	14
3	Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro 2006 ·Journal of Applied Toxicology ·Agneta Oskarsson,Erik Ullerås,Kathryn E. Plant,J. P. Hinson,Peter S. Goldfarb	60
4	Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions 2004 ·Xenobiotica ·David F. Lewis,Brian G. Lake,Maurice Dickins,Peter S. Goldfarb	16
5	Investigation of Enzyme Selectivity in the Human CYP2C Subfamily: Homology Modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 Crystallographic Template 2003 ·Drug metabolism and drug interactions ·D. F. V. Lewis,Maurice Dickins,Brian G. Lake,Peter S. Goldfarb	7
6	Homology modelling of human CYP1A2 based on the CYP2C5 crystallographic template structure 2003 ·Xenobiotica ·David F. Lewis,Brian G. Lake,Maurice Dickins,Yune‐Fang Ueng,Peter S. Goldfarb	20
7	COMPARATIVE STUDIES ON THE CYTOCHROME P450-ASSOCIATED METABOLISM AND INTERACTION POTENTIAL OF SELEGILINE BETWEEN HUMAN LIVER-DERIVED IN VITRO SYSTEMS 2003 ·Drug Metabolism and Disposition ·Jarmo S. Salonen,Leena Nyman,Alan R. Boobis,Robert J. Edwards,Patricia S. Watts,Brian G. Lake,Roger J. Price,A. B. Renwick,M. José Gómez‐Lechón,José V. Castell,Magnus Ingelman‐Sundberg,Mats Hidestrand,André Guillouzo,Laurent Corcos,Peter S. Goldfarb,David F. Lewis,Päivi Taavitsainen,Olavi Pelkonen	55
8	Homology modelling of human CYP2E1 based on the CYP2C5 crystal structure: investigation of enzyme–substrate and enzyme–inhibitor interactions 2003 ·Toxicology in Vitro ·David F. Lewis,Brian G. Lake,Michael G. Bird,George Loizou,Maurice Dickins,Peter S. Goldfarb	30
9	Mutation analysis of the human CYP3A4 gene 5′ regulatory region: population screening using non-radioactive SSCP 2002 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Hossein Hamzeiy,(unknown),Helen J. Edwards,Peter S. Goldfarb	35
10	Are food and environmental toxicants ‘overdetected’ by bioassay? 2002 ·Trends in biotechnology ·Alan Wiseman,(unknown),Peter S. Goldfarb,(unknown)	5
11	Molecular modelling of the human glucocorticoid receptor (hGR) ligand-binding domain (LBD) by homology with the human estrogen receptor α (hERα) LBD: quantitative structure–activity relationships within a series of CYP3A4 inducers where induction is mediated via hGR involvement 2002 ·The Journal of Steroid Biochemistry and Molecular Biology ·David F. Lewis,Malcolm S. Ogg,Peter S. Goldfarb,G. Gordon Gibson	10
12	Molecular Modelling of CYP2B6 Based on Homology with the CYP2C5 Crystal Structure: Analysis of Enzyme-Substrate Interactions 2002 ·Drug metabolism and drug interactions ·David F. Lewis,Brian G. Lake,Maurice Dickins,Peter S. Goldfarb	7
13	Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derivedin vitrosystems 2001 ·Xenobiotica ·Olavi Pelkonen,Päivi Myllynen,Päivi Taavitsainen,Alan R. Boobis,Patricia S. Watts,Brian G. Lake,Roger J. Price,A. B. Renwick,M. José Gómez‐Lechón,José V. Castell,Magnus Ingelman‐Sundberg,Mats Hidestrand,A. Guillouzo,Laurent Corcos,Peter S. Goldfarb,D. F. V. Lewis	49
14	Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102 1999 ·Toxicology ·D. F. V. Lewis,Brian G. Lake,Stephen G. George,(unknown),Peter Eddershaw,Michael H. Tarbit,Alan Beresford,Peter S. Goldfarb,F. Peter Guengerich	49
15	Cytochrome P450 Substrate Specificities, Substrate Structural Templates and Enzyme Active Site Geometries 1999 ·Drug metabolism and drug interactions ·D. F. V. Lewis,Maurice Dickins,Peter Eddershaw,Michael H. Tarbit,Peter S. Goldfarb	59
16	Developmental modulation of cysteine conjugate β-lyase/glutamine transaminase K/kynurenine aminotransferase mRNA in rat brain 1997 ·European Journal of Drug Metabolism and Pharmacokinetics ·Nick Plant,Ian Kitchen,Peter S. Goldfarb,G. Gordon Gibson	7
17	Differing features of proteins in membranes may result in antioxidant or prooxidant action: opposite effects on lipid peroxidation of alcohol dehydrogenase and albumin in liposomal systems 1996 ·Redox Report ·(unknown),Z. Shamsi,(unknown),Peter S. Goldfarb,A. G. Wiseman	6
18	Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals 1996 ·Xenobiotica ·D. F. V. Lewis,Peter Eddershaw,Peter S. Goldfarb,Michael H. Tarbit	80
19	Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strains 1990 ·Biochemical Pharmacology ·(unknown),(unknown),Peter S. Goldfarb,Frank W. Bonner,G. Gordon Gibson	26
20	A human cDNA sequence for a novel glutathione peroxidase-related selenopeptide, GPRP 1989 ·Nucleic Acids Research ·(unknown),(unknown),(unknown),Peter S. Goldfarb	9

About Peter S. Goldfarb

Peter S. Goldfarb is a scholar working on Pharmacology, Toxicology and Biochemistry, having authored 90 papers that have together received 2.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (33 papers), Drug Transport and Resistance Mechanisms (18 papers) and Computational Drug Discovery Methods (12 papers). The work is most often cited by research in Pharmacology (860 citations), Health, Toxicology and Mutagenesis (548 citations) and Biochemistry (230 citations). Peter S. Goldfarb has collaborated with scholars based in United Kingdom, United States and Sweden. Frequent co-authors include Peter Eddershaw, Michael H. Tarbit, David F. Lewis, Nabeel A. Affara, Paul R. Harrison, Ian Chambers, Jon Frampton, David R. Livingstone, Maurice Dickins and Brian G. Lake. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact